Alamar Biosciences, Inc. (ALMR): Results of Operations and Financial Condition
Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance FREMONT, Calif.--August 10, 2026 (GLOBE NEWSWIRE)—Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detectio
How this was made
The 30-second read
Why it matters
Fresh quarterly revenue, margin, and loss metrics plus a full-year revenue range create a direct basis for updating models and near-term expectations ahead of the Aug 10 call.
Market read
The combination of 82% YoY revenue growth and $116M-$120M 2026 guidance midpoint growth (59%) is the core tradable catalyst, with margin and expense trends as the key risk check.
What to watch
Gross margin improved to 60% (from 53%) but operating expenses rose 89% YoY; traders may focus on whether margin expansion is sustainable and how much of growth is consumables versus instrument cyclicality.
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
Total revenue increased 82%, consumable revenue grew 147%, and gross margin expanded to 60%, while operating expenses increased 89% and net loss widened to $13.2 million.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $29.4 million | – | 82% increase |
| Product revenueGAAP | $23,269 | – | – |
| Service and other revenueGAAP | $6,158 | – | – |
| Total cost of revenueGAAP | $11,709 | – | – |
| Gross profitGAAP | $17,718 | – | – |
| Gross marginGAAP | 60% | – | – |
| Research and development expenseGAAP | $13,817 | – | – |
| Selling, general and administrative expenseGAAP | $17,433 | – | – |
| Total operating expensesGAAP | $31.2 million | – | 89% increase |
| Operating lossGAAP | $13.5 million | – | – |
| Interest income, netGAAP | $1,875 | – | – |
| Interest expenseGAAP | $(224) | – | – |
| Loss on remeasurement of convertible notesGAAP | $(1,377) | – | – |
| Net lossGAAP | $13.2 million | – | – |
| Net loss per share, basic and dilutedGAAP | $(0.22) | – | – |
| Weighted-average common shares outstanding, basic and dilutedGAAP | 58,665,055 | – | – |
| Total stock-based compensation expenseGAAP | $3.3 million | – | – |
| Cash, cash equivalents, short-term investments and restricted cashother | $256.3 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| InstrumentsDriven primarily by continued growth in new instrument placements. | $7.8 million | – | 35% |
| ConsumablesDriven primarily by strong demand for multiplex panels. | $15.5 million | – | 147% |
| Services and other revenueDriver not specified. | $6.2 million | – | 49% |
Full year 2026 outlook
- Revenue$116 million to $120 million
- NoteGrowth of 59% at the midpoint of the range compared to full year 2025.
What drove it
- Consumable revenue grew 147%, driven primarily by strong demand for multiplex panels.
- Instrument revenue grew 35%, driven primarily by continued growth in new instrument placements.
- Gross-margin expansion was primarily driven by manufacturing efficiencies for consumables and a favorable shift in mix toward high-margin consumables.
- The company launched the first commercial multiplexed blood-based immunoassay for eMTBR-tau and launched the NULISAseq™ Immune 340 Panel.
Concerns
- Operating expenses increased 89% to $31.2 million, primarily related to planned investments in headcount, infrastructure and R&D capabilities as well as incremental public company costs.
- Net loss increased to $13.2 million from a $7.0 million net loss.
- The quarter included a $1,377 loss on remeasurement of convertible notes.
- The filing identifies risks including intense competition in the proteomics market, dependence on researchers who rely heavily on government funding, reductions in research and academic-institution spending, and manufacturing complexity.
What to watch
- Demand for multiplex panels and the resulting consumable-revenue trajectory.
- New instrument placements and their contribution to instrument revenue.
- Whether manufacturing efficiencies and the mix toward high-margin consumables support gross margin.
- Adoption of eMTBR-tau and the NULISAseq™ Immune 340 Panel.
- Progress toward full-year 2026 revenue guidance of $116 million to $120 million.
- The pace of spending on headcount, infrastructure and R&D capabilities.
Balance sheet and cash flow
- Cash and cash equivalents were $132,969 as of June 30, 2026.
- Short-term investments were $117,083 as of June 30, 2026.
- Restricted cash was $6,254 as of June 30, 2026.
- Term debt was $9,947 as of June 30, 2026.
- No operating cash flow, free cash flow, repurchases, or dividends were reported.
Analysis
Alamar reported $29.4 million of second-quarter revenue, up 82% from $16.2 million in the corresponding prior-year period. Growth was led by consumables, which rose 147% to $15.5 million on strong demand for multiplex panels. Instrument revenue increased 35% to $7.8 million, driven primarily by new instrument placements, while services and other revenue increased 49% to $6.2 million.
The revenue mix supported profitability at the gross-profit level. Gross margin increased to 60% from 53%, with the company attributing the improvement to consumables manufacturing efficiencies and a favorable shift toward high-margin consumables. Gross profit was $17,718, compared with $8,581 in the prior-year quarter, based on the condensed consolidated statements of operations.
Operating investment rose faster than revenue. Operating expenses increased 89% to $31.2 million, reflecting planned investments in headcount, infrastructure and R&D capabilities as well as incremental public company costs. Operating loss was $13.5 million versus an operating loss of $7.9 million, and net loss was $13.2 million compared with a $7.0 million net loss. The quarter included $3.3 million of stock-based compensation and a $1,377 loss on remeasurement of convertible notes.
Liquidity was $256.3 million in cash, cash equivalents, short-term investments and restricted cash as of June 30, 2026. The company provided full-year 2026 revenue guidance of $116 million to $120 million, representing growth of 59% at the midpoint compared with full-year 2025. The key operating indicators are sustained consumables demand, continued instrument placements, commercialization of eMTBR-tau and the Immune 340 Panel, and the relationship between spending growth and further gross-margin expansion.
Management, verbatim
We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year.
Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences
With the recent launches of eMTBR-tau and the Immune 340 Panel strengthening our content menu and extending into new disease areas, we believe we are well-positioned to sustain momentum into the coming quarters.
Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences
Not in the filing
stated, not guessed- Previous-quarter revenue, segment revenue, gross margin, operating expenses, operating loss, net loss, EPS, and cash-flow comparisons were not reported.
- Non-GAAP revenue, gross margin, operating income or loss, net income or loss, and EPS were not reported.
- Operating cash flow and free cash flow were not reported.
- Share repurchases and dividends were not reported.
- Guidance for gross margin, operating expenses, tax rate, EPS, operating cash flow, or free cash flow was not reported.
- Prior guidance was not provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC 8-K (Item 2.02) with Exhibit 99.1 covering Q2 2026 results and full-year 2026 revenue guidance.
Ticker impact
Alamar reported Q2 2026 revenue of $29.4M (+82% YoY) and guided full-year 2026 revenue to $116M-$120M.
Likely positive bias for ALMR as guidance midpoint implies 59% growth, but watch for market focus on operating loss and cash burn.
The article provides specific, time-stamped financial results (revenue, gross margin, operating loss, cash) and a concrete 2026 revenue guidance range, which are direct inputs to valuation and forward estimates.
Market effects
Signals demand strength for multiplex proteomics consumables and instrument placements, potentially supportive for sentiment toward precision proteomics peers.
Limited direct regional spillover; primarily company-specific.
Modest, as it is a single-company proteomics update rather than a sector-wide regulatory or macro catalyst.
Counterpoint
Despite revenue growth, operating expenses surged and operating loss widened, so the market may discount growth if cash burn accelerates.
Key entities
- issuerAlamar Biosciences, Inc.
Precision proteomics company reporting Q2 2026 financial results and 2026 revenue guidance.
- productNULISAseq eMTBR-tau and Immune 340 Panel
New multiplexed blood-based immunoassays referenced as drivers of demand and content expansion.
- instrumentARGO HT System
Instrument platform whose placements contributed to instrument revenue growth.
